BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Gan & Lee Pharmaceuticals readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Gan & Lee Pharmaceuticals's drugs
  run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07387003-443@assetmemo.bio
DTSTAMP:20261121T010439Z
DTSTART;VALUE=DATE:20270211
DTEND;VALUE=DATE:20270212
SUMMARY:GZR101: Phase 2 readout est. (NCT07387003)
DESCRIPTION:GZR101\, phase 2\, Type 2 Diabetes.\nStudy: Evaluate the Effica
 cy and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes\nEst
 imated primary completion: 11 February 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/gzr101#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07387003
URL:https://assetmemo.bio/drug/gzr101#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07150975-190@assetmemo.bio
DTSTAMP:20261121T010439Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Bofanglutide: Phase 3 readout est. (NCT07150975)
DESCRIPTION:Bofanglutide\, phase 3\, Obesity.\nStudy: Phase III Clinical St
 udy Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (
 Wegovy®) in Adult Obese or Overweight Subjects\nEstimated primary complet
 ion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bo
 fanglutide#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07150975
URL:https://assetmemo.bio/drug/bofanglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07493057-190@assetmemo.bio
DTSTAMP:20261121T010439Z
DTSTART;VALUE=DATE:20271114
DTEND;VALUE=DATE:20271115
SUMMARY:Bofanglutide: Phase 3 readout est. (NCT07493057)
DESCRIPTION:Bofanglutide\, phase 3\, Obesity.\nStudy: Evaluate the Efficacy
  and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Ap
 nea Not Treated With Positive Airway Pressure (PAP) Therapy\nEstimated pri
 mary completion: 14 November 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/bofanglutide#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07493057
URL:https://assetmemo.bio/drug/bofanglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07501832-190@assetmemo.bio
DTSTAMP:20261121T010439Z
DTSTART;VALUE=DATE:20280928
DTEND;VALUE=DATE:20280929
SUMMARY:Bofanglutide: Phase 3 readout est. (NCT07501832)
DESCRIPTION:Bofanglutide\, phase 3\, Obesity.\nStudy: Evaluate the Efficacy
  and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Ap
 nea Receiving Positive Airway Pressure (PAP) Therapy\nEstimated primary co
 mpletion: 28 September 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/bofanglutide#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07501832
URL:https://assetmemo.bio/drug/bofanglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
